Similar articles for PMID: 18208367

Year	Number of Results
2003	2
2004	1
2005	3
2006	7
2007	7
2008	4
2009	4
2010	2
2011	3
2012	3
2013	4
2014	4
2015	14
2016	13
2017	5
2018	5
2019	5
2021	2
2022	1
2023	1
2024	0

1

Therapeutic potential of CB2 targeting in multiple sclerosis.

Docagne F, Mestre L, Loría F, Hernangómez M, Correa F, Guaza C. Docagne F, et al. Expert Opin Ther Targets. 2008 Feb;12(2):185-95. doi: 10.1517/14728222.12.2.185. Expert Opin Ther Targets. 2008. PMID: 18208367 Review.

2

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.

Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. Shoemaker JL, et al. J Neurochem. 2007 Apr;101(1):87-98. doi: 10.1111/j.1471-4159.2006.04346.x. Epub 2007 Jan 4. J Neurochem. 2007. PMID: 17241118 Free PMC article.

3

Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.

Malfitano AM, Laezza C, D'Alessandro A, Procaccini C, Saccomanni G, Tuccinardi T, Manera C, Macchia M, Matarese G, Gazzerro P, Bifulco M. Malfitano AM, et al. PLoS One. 2013 May 1;8(5):e62511. doi: 10.1371/journal.pone.0062511. Print 2013. PLoS One. 2013. PMID: 23658734 Free PMC article.

4

Role of CB2 receptors in neuroprotective effects of cannabinoids.

Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA. Fernández-Ruiz J, et al. Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S91-6. doi: 10.1016/j.mce.2008.01.001. Epub 2008 Jan 17. Mol Cell Endocrinol. 2008. PMID: 18291574 Review.

5

Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.

Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR. Gómez-Cañas M, et al. Pharmacol Res. 2016 Aug;110:205-215. doi: 10.1016/j.phrs.2016.03.021. Epub 2016 Mar 22. Pharmacol Res. 2016. PMID: 27013280

6

Neuroprotective agents: cannabinoids.

Sánchez AJ, García-Merino A. Sánchez AJ, et al. Clin Immunol. 2012 Jan;142(1):57-67. doi: 10.1016/j.clim.2011.02.010. Epub 2011 Mar 21. Clin Immunol. 2012. PMID: 21420365 Review.

7

Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.

Annunziata P, Cioni C, Mugnaini C, Corelli F. Annunziata P, et al. J Neuroimmunol. 2017 Feb 15;303:66-74. doi: 10.1016/j.jneuroim.2016.12.009. Epub 2016 Dec 23. J Neuroimmunol. 2017. PMID: 28041663

8

Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

Pryce G, Baker D. Pryce G, et al. Handb Exp Pharmacol. 2015;231:213-31. doi: 10.1007/978-3-319-20825-1_7. Handb Exp Pharmacol. 2015. PMID: 26408162 Review.

9

Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.

Docagne F, Muñetón V, Clemente D, Ali C, Loría F, Correa F, Hernangómez M, Mestre L, Vivien D, Guaza C. Docagne F, et al. Mol Cell Neurosci. 2007 Apr;34(4):551-61. doi: 10.1016/j.mcn.2006.12.005. Epub 2007 Jan 16. Mol Cell Neurosci. 2007. PMID: 17229577

10

Cannabinoid receptor 2 activation restricts fibrosis and alleviates hydrocephalus after intraventricular hemorrhage.

Tan Q, Chen Q, Feng Z, Shi X, Tang J, Tao Y, Jiang B, Tan L, Feng H, Zhu G, Yang Y, Chen Z. Tan Q, et al. Brain Res. 2017 Jan 1;1654(Pt A):24-33. doi: 10.1016/j.brainres.2016.10.016. Epub 2016 Oct 18. Brain Res. 2017. PMID: 27769788

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

78 results

Results by year